1. Home
  2. STTK

as 11-15-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.

Founded: 2016 Country:
United States
United States
Employees: N/A City: AUSTIN
Market Cap: 59.7M IPO Year: 2020
Target Price: $2.00 AVG Volume (30 days): 357.1K
Analyst Decision: Hold Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.52 EPS Growth: N/A
52 Week Low/High: $1.07 - $11.76 Next Earning Date: 11-14-2024
Revenue: $6,435,000 Revenue Growth: 382.75%
Revenue Growth (this year): 115.09% Revenue Growth (next year): N/A

STTK Daily Stock ML Predictions

Stock Insider Trading Activity of Shattuck Labs Inc. (STTK)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Schreiber Taylor STTK Chief Executive Officer Oct 7 '24 Buy $1.21 36,500 $44,219.75 71,002

Share on Social Networks: